HalioDx has developed customized services to guide biopharmas in their clinical programs and help them to predict patient response to immunotherapy.
To get a full insight into the tumor immune contexture, you can also access to our Atlas customized multimarker database designed for each cancer indication.
We provide a high level of support to our partners ensuring a successful biomarker strategy approach during your clinical trials, from early phase to late stage.
Our expert dedicated team along with our capabilities in development, clinical research, manufacturing, regulatory and commercialization will accompany each of our pharma partners in their project with a tailored and personalized approach depending on their needs :
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Nature Reviews Cancer
AACR2020 Abstract # 5970
Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Tumor Immunology and Tumor Evolution: Intertwined Histories
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
HalioDx Biopharma Services
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
Evolution of Metastases in Space and Time under Immune Selection.
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.